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PENILAIAN ANALITIKAL INTERAKSI DRUG-DRUG SECARA IN VITRO 
BAGI TERAPI KOMBINASI ARTESUNATE TETAP: ABSTRAK 
Plasmodium falciparum yang rintang ubat kini merupakan suatu ancaman serius, 
terutamanya di kawasan-kawasan tertentu dunia di mana malaria adalah endemik. 
Oleh itu, pihak WHO mengesyorkan regimen kombinasi seperti artesunat-
meflokuina dan artesunate-amodiakuina sebagai rawatan utama bagi penyakit 
malaria terutamanya di kawasan-kawasan di mana parasit falciparum adalah paling 
rintang. Walau bagaimanapun, kajian interaksi drug in vitro bagi kombinasi 
artesunat-meflokuina dan artesunate-amodiakuina belum pernah dijalankan. 
Teknik experimen in vitro mikrosom hepar manusia digunakan untuk mengkaji 
metabolisme artesunat secara bersendirian dan juga dengan kehadiran mefloquina 
dan amodiakuina. Penentuan serentak artesunat, dihidroartemisinin dan artemisinin 
dalam sampel mikrosom dijalankan menggunakan kaedah kromatografi cecair 
tekanan tinggi yang dilengkapi dengan pengesan elektrokimia. Kajian ini 
menunjukkan bahawa apabila diinkubasi secara in vitro dengan mikrosom, artesunat 
dimetabolisme kepada dihidroartemisinin, dimangkin oleh enzim CYP450 . 
Kajian in vitro ini juga menunjukkan bahawa tindak balas metabolisme artesunat 
tidak dipengaruhi oleh tindak balas metabolisme meflokuina ataupun amodiakuina 
pada kepekatan terapeutik. Ketiadaan interaksi di antara drug-drug ini memberi 
kesimpulan bahawa kombinasi artesunat-meflokuina dan artesunate-amodiakuina 
adalah rawatan anti-malaria yang berkesan dan selamat apabila digunakan pada 
kepekatan terapeutik. Walau bagaimanpun, kajian klinikal bagi kedua-dua kombinasi 
ini perlu dijalankan bagi menyokong penemuaan kajian ini. 
xx 
 
AN ANALYTICAL EVALUATION OF IN VITRO DRUG-DRUG 
INTERACTION STUDIES FOR FIXED ARTESUNATE COMBINATION 
THERAPY: ABSTRACT 
 
Drug-resistant Plasmodium falciparum has become a serious threat, especially in 
malaria-endemic regions of the world. In light of this, the WHO has recommended 
artemisinin combination therapy such as artesunate-mefloquine and artesunate-
amodiaquine as first line treatment for uncomplicated falciparum malaria especially 
in regions harbouring the most resistant isolates. However, the in vitro drug 
interaction studies have not been conducted for both these combinations.  
An in vitro experimental technique, utilizing human liver microsomes was used to 
study the metabolism of AS in the presence and absence of mefloquine and 
amodiaquine. Simultaneous determination of artesunate, dihydroartemisinin and 
artemisinin in microsomal sample was performed using high performance liquid 
chromatography- electrochemical (HPLC-EC) method. The study shows that 
artesunate is metabolised to dihydroartemisinin in the in vitro microsomal assay. The 
reaction is mediated by CYP450 enzymes present in the microsomal assay.  
The metabolism of artesunate was not affected by mefloquine or amodiaquine at 
therapeutic concentrations using the in vitro microsomal technique. The absence of 
interactions between these drugs led to the conclusion that the artesunate-mefloquine 
and artesunate-amodiaquine combinations are ideal and safe treatments when used in 
therapeutic concentrations. However, further clinical studies must be done to confirm 
these findings. 
 
1 
 
CHAPTER 1:  INTRODUCTION 
1.1. Global Malaria Scene 
Malaria is a vector-borne infectious disease caused by protozoan parasites. It is 
widespread in tropical and subtropical regions of the world, including parts of the 
Americas, Asia, and Africa (Figure 1.1). Still, malaria continues to receive 
insufficient attention since industrial and financial powers are concentrated in 
temperate countries where malaria is no longer a threat. For this reason, malaria is 
considered a neglected disease (Carmargo, de Oliveira, Basano, & Garcia, 2009).  
It has been documented that malaria pre-dates the evolution of man and the malarial 
parasite is known to have been a human pathogen for the entire history of its species 
(Joy, et al., 2003); (Hayakawa, Culleton, Otani, Horii, & Tanabe, 2008). The first 
evidence of malaria dates back to as far as 30 million years ago (Poinar, 2005) with 
historical records of the disease dating back to more than 3000 years ago (Sherman, 
1998a); (Harrison, 1979); (Bruce-Chwat, 1988). However, the discovery of the 
causative agent of malaria only took place in 1880 by a French army doctor working 
in the military hospital of Constantine in Algeria , Charles Louis Alphonse Laveran 
(1845-1922). Laveran observed parasites for the first time, inside the erythrocytes of 
patients suffering from malaria and was awarded the Nobel Prize for his discovery.  
Malaria causes about 250 million cases of fever and approximately 1 million deaths 
annually (World Health Organisation (WHO), 2008). Most of these cases occur in 
children under 5 years of age (Greenwood, Bojang, Whitty, Targett, & GA., Malaria, 
2005).  Approximately one infant dies of malaria every 30 seconds (Carmargo, de 
Oliveira, Basano, & Garcia, 2009). Pregnant women are also especially vulnerable. 
Pregnancy reduces a woman’s immunity to malaria, making her more susceptible to 
2 
 
malaria parasite infections and other illnesses including severe anaemia and in 
extreme cases, even death. 
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Figure 1. 1. Malaria-free and malaria-endemic countries in phases of control, pre-elimination, elimination, and prevention of re-
introduction 
Source: World Malaria Report 2008, World Health Organisation, 2008 
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For the foetus, maternal malaria is one of the leading causes of child mortality, with 
higher risks of spontaneous abortion, stillbirth, premature delivery and low birth 
weight (http://www.who.int/features/2003/04b/en/, 2003). 
Uncomplicated malaria is the mild form of the disease which occurs as a febrile 
illness with headache, tiredness, muscle pains, abdominal pains, rigors (severe 
shivering), and nausea and vomiting. If left untreated, P. falciparum malaria can 
rapidly develop into severe malaria with anaemia (low haemoglobin in the blood), 
hypoglycaemia (low blood sugar), renal failure (kidney failure), pulmonary oedema 
(fluid in the lungs), convulsions, coma, and eventually death (World Health 
Organization (WHO), 2006). 
Despite efforts to reduce transmission and increase treatments, there has been little 
change in malaria high-risk areas since 1992 (Hay, Guerra, Tatem, Noor, & Snow, 
2004). If the prevalence of malaria continues, the death rate could double in the next 
twenty years (Bremen, 2001). Precise statistics are unknown because many cases 
occur in rural areas where people do not have access to hospitals or the means to 
afford health care. As a consequence, the majority of cases are undocumented 
(Bremen, 2001). 
Malaria is presently endemic around the equator, in areas of the Americas, many 
parts of Asia, and much of Africa (Figure 1.1). In fact, in sub-Saharan Africa, 
malaria fatalities are about 85– 90% (Layne, 2005). Malaria is more common in rural 
areas than in cities; this is in contrast to dengue fever where urban areas present the 
greater risk (Van Benthem, et al., 2005). For example, the cities of Vietnam, Laos 
and Cambodia are essentially malaria-free, but the disease is present in many rural 
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regions (Trung H, 2004). By contrast, malaria in Africa is present in both rural and 
urban areas, though the risk is lower in the larger cities (Keiser J, 2004).  
 
1.2. Malaria in Malaysia 
Malaria is still the most important endemic disease in Malaysia, especially in remote 
areas. The first documented case of malaria fever (known then as ‘Pinang fever’) in 
Malaysia was in 1830 in Penang Island (Ward & Grant, 1830). Today, in spite of 
more than 30 years of active malaria control and eradication activities, the disease 
remains prevalent.  
In 1901, the first organized anti-malarial campaign in Malaysia (then known as 
Malaya until 1957) was launched, spearheaded by Sir (Dr.) Malcolm Watson and it 
went on to be described as the first successful anti-malarial effort in the British 
Empire (Watson M. S., 1935). The campaign brought about a major reduction in 
malaria-caused deaths in Klang and Port Swettenham, from 368 deaths in 1901 to 59 
deaths in 1902. A key activity that contributed significantly to the success of the 
campaign was the introduction of the drainage system, devised to control the 
Anopheles mosquitoes. This eventually led to other, better devised methods such as 
agitation ponds, automatic siphons and flush gates, some of which are still used 
today. 
Prior to 1904, the management of malaria in Malaya was based on vector-control. 
However, with the growing global use of the anti-malarial drug quinine to treat 
malaria after its formal discovery by the Jesuit priests, drug therapy using quinine 
was used on a large scale. The discovery of synthetic anti-malarial drugs for 
treatment and prophylaxis from 1930 onwards propelled the malaria control efforts 
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further ahead. With the discovery of the effective insecticide 
dichlorodiphenyltrichloroethane (DDT) by Muller and Weisman in 1936 and further 
advances in chemotherapy, malaria eradication programmes were introduced 
worldwide. In Malaysia, the malaria eradication pilot project was launched in 1967 
with the help of the WHO. Although the programme did not completely eradicate 
malaria in Malaysia, it successfully reduced annual death numbers of 250,000 in 
1961 to 40,000 by the 1970es.  
By 1980es however, difficulties in obtaining the large financial resources required 
for successful malaria eradication, development of successful insecticides and 
emergence of drug-resistant malarial parasites all led to malaria control programmes 
being established in place of malaria eradication programmes. Subsequently these 
programmes were integrated with other control programmes for diseases such as 
dengue, filariasis, Japanese encephalitis, typhus, plague and yellow fever. Among the 
strategies adopted in the malaria control programme were: 
 Improving early diagnosis of malaria disease and its treatment 
 Creating greater awareness of the seriousness of malaria 
 Promoting the use of pyrethroid-treated mosquito nets 
 Improving epidemiological data collection 
 Improving and strengthening management and supervision 
 Improving national and international training capabilities 
 Operational research 
 Development of malaria control staff 
 Integration with other disease control programmes  
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In 1990, the number of reported malaria cases was 50,500 but this value decreased 
by 75% by year 2000 (Figure 1.2). Despite high numbers of reported cases, the 
number of malaria-caused deaths in 1990 was only 43 and only 35 in 2000 (World 
Health Organisation (WHO), 2008). With the development of anti-malarial drugs and 
the application of various methods of vector control, the number of reported malaria-
related cases and incidence rates continues to undergo a steady decline (Figure 1.3). 
 
 
Figure 1. 2. Malaria Incidence from 1961 until May 2007 
Source: Department of Public Health, Ministry of Health Malaysia, 2008 
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Figure 1. 3. Malaria Cases and Incidence Rate in from 1995- May 2007 
Source: Department of Public Health, Ministry of Health Malaysia, 2008 
 
Today, malaria is still a significant public health problem in Malaysia (Lim, 1998); 
(Ministry of Health Malaysia, 2002); (Ministry of Health Malaysia, 2004); (Jamaiah, 
Anuar, Najib, & Zurainee, 1998). The location of Malaysia at the equator, combined 
with optimal temperatures and humidity facilitates rapid growth and transmission of 
malaria parasites and vector (Rahman, Che’ Rus, & Ahmad, 1997).  
Although malaria incidence rates are higher in rural areas (86.5%) such as Sabah and 
Sarawak (Figure 1.4) and among the Orang Asli (33.1%) (Ministry of Health 
Malaysia, 2004), a recent study reported that migrant workers, namely from malaria-
endemic countries such as Indonesia, India, Vietnam, Myanmar, and Pakistan (Lim, 
1998); (Vijayakumari, 2006) are mainly responsible (up to 60% contribution) for the 
spread of malaria in Malaysian urban areas (Masitah, Nor aini, & Mas Ayu, 2008). 
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Figure 1. 4. Malaria Cases and Incidence Rate in Malaysia by State until May 2007 
Source: Department of Public Health, Ministry of Health Malaysia, 2008 
 
Another study reported that malaria recurrently occurred more often among foreign 
patients (57%) in University Malaya Medical Centre (UMMC) than Malaysian 
patients (43%) (Jamaiah I, 1998). Between the years 1983 to 1992, the number of 
malaria cases among foreigners in Malaysia had increased by 33%. With the annual 
increase of foreign workers influx into Malaysia, this percentage increase is not 
surprising. 
In many malaria-endemic countries outside the African continent such as Malaysia, 
P. vivax coexists with P. Falciparum (Korsinczky, Fischer, Chen, Baker, Rieckmann, 
& Cheng, 2004). Plasmodium vivax is the most common strain of malaria parasite in 
Malaysia, followed by P. Falciparum (Figure 1.5). A study reported that P. vivax 
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was the most common infection in northern peninsular Malaysia, bordering Thailand, 
but P. falciparum and mixed infections also occurred (Rahman, Abu Hassan, 
Adanan, & Rashid, 1993). 
 
 
Figure 1. 5. Malaria Parasite Distribution in Malaysia until May 2007 
Source: Department of Public Health, Ministry of Health Malaysia, 2008 
 
1.3. The Mechanism of Malaria 
The causative agent of malaria is a protozoan parasite of the genus Plasmodium 
(phylum Apicomplexa). In humans, the etiologic agents of malaria are the multistage 
P. falciparum, P. malariae, P. ovale, P. vivax and P. knowlesi (Mueller, Zimmerman, 
& Reeder, 2007); (Singh, et al., 2004). P. falciparum is the most common cause of 
infection and is responsible for about 80% of all malaria cases and 90% of malaria-
caused deaths (Mendis, Sina, Marchesini, & Carter, 2001). The Plasmodium species, 
with the exception of P.malariae (which may affect the higher primates) are 
exclusively parasites of man. 
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The life cycle of Plasmodium is shown in Figure 1.6. The parasite's primary 
(definitive) hosts and transmission vectors are adult female mosquitoes of the 
Anopheles genus (Ross, 1897); (Holt, et al., 2002). Only female Anopheles 
mosquitoes (Figure 1.7) feed on blood, thus males do not transmit the disease. Out of 
the 380 species of Anopheles mosquito, only 60 can transmit malaria. Malaria 
parasites can also be transmitted by blood transfusions, although this is rare 
(Marcucci, Madjdpour, & Spahn, 2004).  
Uninfected mosquitoes first ingest the malaria parasite by feeding on an infected 
human (host) carrier. During ingestion of a blood meal from an infected host, the 
parasites enter the female Anopheles’ digestive system in the male and female sexual 
forms called gametocytes. Both male and female gametocytes then undergo rapid 
cellular division to form male and female gametes called microgametes and 
macrogametes respectively. The flagellated microgametes then fertilize the 
macrogametes by fusing with it in the mid-gut of the female Anopheles. The 
fertilization process produces an ookinete that penetrates the gut lining and produces 
an oocyst in the gut wall. When the oocyst ruptures, it releases sporozoites that 
migrate through the mosquito's body to the salivary glands, where they are then 
ready to infect a new human host. When the mosquito takes a subsequent blood 
meal, the motile, infective sporozoites are injected into the victim’s skin capillaries, 
with the Anopheles’ saliva and pass into the human’s bloodstream. This type of 
transmission is occasionally referred to as anterior station transfer (Talman, Domarle, 
McKenzie, Ariey, & Robert, 2004).  
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Figure 1. 6. Lifecycle of Plasmodium falciparum 
Source: http://www.nap.edu/books/0309092183/xhtml/images/p2000af94g137001.jpg 
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Figure 1. 7. A Feeding female Anopheles mosquito 
Source: http://www.arbovirus.health.nsw.gov.au 
 
Figure 1. 8. Different Life Stages of Plasmodium falciparum 
Source: http://img.medscape.com 
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Once in the human body, the malaria parasite develops via two phases: an 
exoerythrocytic and an erythrocytic phase. The exoerythrocytic phase involves 
infection of the hepatic system, or liver, whereas the erythrocytic phase involves 
infection of the erythrocytes, or red blood cells. When an infected mosquito pierces a 
person's skin to take a blood meal, sporozoites in the mosquito's saliva enter the 
bloodstream and migrate to the liver. Within 30 minutes of being inoculated into the 
human host, the sporozoites disappear from the blood. Many are destroyed by the 
human body’s phagocytes but some enter the hepatocytes (parenchyma cells of the 
liver) directly or via the Kupffer cells. In the hepatocytes, the sporozoites multiply 
asexually and asymptomatically in a process called exoerythrocytic schizogony for a 
period of 6–15 days. During this process, multinucleated schizonts are formed. The 
cytoplasm of each schizont divides in a manner that results in the encapsulation of 
each nucleus, such that each encapsulated nucleus forms a merozoite. About 2000 to 
40,000 merozoites can be formed in the liver depending on the species of 
Plasmodium. The merozoites then undergo maturation in the hepatocytes. The 
merozoite-containing hepatocytes eventually rupture, releasing the mature 
merozoites into the blood. Despite the numerous defence mechanisms present in the 
internal body systems, the merozoites escape from the liver undetected. This is done 
by wrapping themselves in the cell membrane of the infected host liver cell (Sturm, 
et al., 2006). The released merozoites then invade the erythrocytes, thus beginning 
the erythrocytic stage of the life cycle (Bledsoe, 2005). Figure 1.8 shows the 
different life stages of the Plasmodium falciparum. 
In the erythrocytic stage, the released merozoites invade the erythrocytes present in 
the sinusoids of the liver while some are phagocytised. Within the erythrocytes, the 
merozoites undergo a trophic period, in which they enlarge and again multiply 
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asexually, periodically breaking out of their host erythrocyte to invade fresh 
erythrocytes. Several such amplification cycles occur, significantly destroying many 
erythrocytes in order to release mature merozoites. Following the lysis of 
erythrocytes to release mature merozoites, a glycolipid with many properties of 
bacterial endotoxins is released, causing a cascade reaction. The glycolipid activates 
cytokines such as tumour necrosis factor (TNF) and interleukins II-1, II-6 and II-8 
(Stein, 1983) and other unidentified pyrogenic substances that leads to paroxysms of 
malarial fever and malaise  Thus, classical descriptions of waves of fever arise from 
simultaneous waves of merozoites escaping and infecting red blood cells. 
Some P. vivax and P. ovale sporozoites do not immediately develop into 
exoerythrocytic-phase merozoites, but instead produce hypnozoites that remain 
dormant for periods ranging from several months (6–12 months is typical) to as long 
as three years. After a period of dormancy, they reactivate and produce merozoites. 
Hypnozoites are responsible for long incubation and late relapses in these two 
species of malaria (Cogswell, 1992). 
The Plasmodium parasite is relatively protected from attack by the body's immune 
system because for most of its human life cycle it resides within the liver and 
erythrocyes and is relatively invisible to immune surveillance. However, circulating 
infected erythrocytes are destroyed in the spleen. To avoid this fate, the P. 
falciparum parasite displays adhesive proteins on the surface of the infected 
erythrocytes, causing the erythrocytes to adhere to the walls of small blood vessels, 
thereby sequestering the parasite from passage through the general circulation and 
the spleen (Chen, Schlichtherle, & Wahlgren, 2000). This "adherence" is the main 
factor that gives rise to hemorrhagic complications of malaria. High endothelial 
venules (the smallest branches of the circulatory system) can be blocked by the 
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attachment of masses of these infected erythrocytes. The blockage of these vessels 
causes symptoms such as in placental and cerebral malaria. In cerebral malaria the 
sequestrated erythrocytes can breach the blood brain barrier possibly leading to coma 
(Adams, Brown, & Turner, 2002). 
Some merozoites in the blood turn into male and female gametocytes. If a mosquito 
pierces the skin of an infected person, it potentially picks up gametocytes within the 
blood. Fertilization and sexual recombination of the parasite occurs in the mosquito's 
gut, thereby defining the mosquito as the definitive host of the disease. New 
sporozoites develop and travel to the mosquito's salivary gland, completing the cycle. 
Pregnant women are especially attractive to the mosquitoes due to hormonal, 
metabolic, or mechanical (increased expression of adherence factors in placenta 
enhancing the conditions for P. falciparum development) changes (Lindsay, Ansell, 
Selman, Cox, Hamilton, & Walraven, 2000). Malaria in pregnant women is a major 
cause of stillbirths, infant mortality and low birth weight (van Geertruyden, Thomas, 
Erhart, & D'Alessandro, 2004), particularly by P. falciparum infections, but also by 
other species infection, such as P. vivax (Rodriguez-Morales, et al., 2006). 
 
1.4. Methods in Malaria Control 
Methods used to prevent the spread of disease, or to protect individuals in areas 
where malaria is endemic, include prophylactic drugs, mosquito eradication, and the 
prevention of mosquito bites. The continued existence of malaria in an area requires 
a combination of high human population density, high mosquito population density, 
and high rates of transmission from humans to mosquitoes and from mosquitoes to 
humans. If any of these is lowered sufficiently, the parasite will eventually disappear 
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from that area, which occured in North America, Europe and much of Middle East. 
However, unless the parasite is eliminated globally, it could re-establish if conditions 
revert to a combination that favours the parasite's reproduction. Many countries are 
observing an increasing number of imported malaria cases due to extensive travel 
and migration.  
Efforts to eradicate malaria by eliminating mosquitoes have been successful in some 
areas. In the United States of America, the draining of wetland breeding grounds, 
better sanitation, and the use of the pesticides eliminated mosquitoes and led to the 
reduction of malaria cases ( http://www.cdc.gov/malaria/history/eradication_us.htm, 
2004). Before pesticides were used, malaria was successfully eradicated or controlled 
also in several tropical areas by removing or poisoning the breeding grounds of the 
mosquitoes or the aquatic habitats of the larva stages.  
Sterile insect technique is also emerging as a potential mosquito control method. 
Progress towards genetically modified insects suggests that wild mosquito 
populations could be made malaria-resistant. Researchers at Imperial College 
London in 2000, created the world's first transgenic malaria mosquito (Catteruccia, et 
al., 2000) and the first Plasmodium-resistant species was produced by a team at Case 
Western Reserve University in Ohio in 2002 (Ito, Ghosh, Moreira, Wimmer, & 
Jacobs-Lorena, 2002). Following that, a separate published study found that a 
chemical produced by sea cucumber Cucumaria echinata, impaired the development 
of the malaria parasites produced by transgenic mosquitoes (Yoshida, et al., 2007).  
Indoor residual spraying (IRS) is the practice of spraying insecticides on the interior 
walls of homes in malaria-infected areas. After feeding, many mosquito species rest 
on nearby surfaces while digesting the blood meal. Therefore, insecticide-coated 
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walls of dwellings could eliminate mosquitoes before they inject another victim, 
transferring the malaria parasite. The first and historically most effective insecticide 
used for IRS was DDT. Initially it was used exclusively to combat malaria. However, 
its use quickly spread to agriculture. This large-scale use led to the evolution of 
resistant mosquitoes in many regions of the world. The DDT resistance shown by the 
Anopheles mosquitoes is comparable to antibiotic resistance exhibited by bacteria. 
Despite its effectiveness, awareness of the negative consequences of DDT overuse 
led it to be banned from agricultural applications in many countries. It is likely that 
DDT may now be more effective method of malaria control since its use has been 
limited or banned for some time. 
Mosquito nets hinder direct contact between mosquitoes and people, greatly reducing 
the infection and transmission of malaria. Nevertheless, nets are not perfect barriers. 
As such, they are often treated with insecticides (insecticide-treated nets, ITN) 
designed to kill the mosquito before it has time to search for a way past the net. ITN 
are estimated to be twice as effective as untreated nets (Hull, 2006) and offer greater 
than 70% protection compared to absence of net (Bachou, Tylleskär, Kaddu-
Mulindwa, & Tumwine, 2006).  
 
1.5. Treatment of Malaria 
For most infectious diseases for which there are effective vaccines, a single infection 
confers long-standing protective immunity. However, this type of protective 
immunity does not exist for malaria. There is currently no licensed vaccine that will 
prevent malaria (Plowe, Alonso, & Hoffman, 2009), but this is an active field of 
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research. Vaccines for malaria are under development, with no completely effective 
vaccine yet available. However, there are antimalarial medications. 
Malaria is treated with antimalarial drugs. Antimalarials can be classified as 
prophylactic and therapy drugs. Prophylactic drugs are taken as prevention and 
require continuous administration to reduce the risk of infection. Therapy drugs on 
the other hand are taken when the person is already infected with Plasmodium. 
However, strategies for combating malaria change rapidly, and when drugs are 
administered in combination, it can be difficult to identify which agents are 
prophylactic and which are therapeutic. Another approach for classifying 
antimalarials is to group them by mechanism of action and by chemical structure. 
Based on this type of classification, there are the following three groups of 
antimalarials: the quinolines, antifolates, and the artemisinin derivatives. 
 
1.5.1. Quinolines 
The first quinoline antimalarials were alkaloids extracted from the cinchona tree. 
There are 3 groups of quinolines developed as antimalarials. They are the 8-
aminoquinolines, 4-aminoquinolines, and quinolinemethanols. The first synthetic 
antimalarial was an 8-aminoquinoline called plasmaquine (later called Pamaquine) 
that was found to be very effective but too toxic. A less toxic analogue called 
primaquine (PR) was synthesized and is still utilized until today to destroy liver 
reservoirs of Plasmodium. Figure 1.9 shows the structure of major quinoline drugs. 
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1.5.1(a) Quinine 
Quinine is a natural white crystalline alkaloid with a bitter taste and has antipyretic 
(fever-reducing), antimalarial, analgesic (painkilling), and anti-inflammatory 
properties. It is a stereoisomer of quinidine. Quinine was the first effective treatment 
for malaria caused by P. falciparum. It remained the antimalarial drug of choice until 
the 1940s. Since then, many other effective antimalarials have been introduced, 
although quinine is still used to treat the disease in certain critical situations.  
Quinine is an alkaloid that acts as a blood schizonticidal and weak gametocide 
against P. vivax and P. malariae. As an alkaloid, it is accumulated in the food 
vacuoles of the Plasmodium species, especially P. falciparum. It acts by facilitating 
an aggregation of cytotoxic heme. Quinine is less effective and more toxic as a blood 
schizonticidal agent than another aminoquinoline, chloroquine (CQ). However it is 
still very effective and widely used in the treatment of acute cases of severe P. 
falciparum. It is especially useful in areas where there is known to be a high level of 
resistance to CQ, mefloquine (MQ) and pyrimethamine (PYR). Quinine is also used 
in post-exposure treatment of individuals returning from an area where malaria is 
endemic. Quinidine is a direct derivative of quinine. It has similar anti-malarial 
properties to the parent compound. Quinidine is recommended only for the treatment 
of severe cases of malaria. 
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Figure 1. 9. Structures of Major Quinoline Drugs 
 
1.5.1(b) Chloroquine (CQ) 
CQ is perhaps one of the earliest and effective 4-aminoquinolines to have been 
produced. It is metabolized by hepatic CYPs 2C8, 3A4 and 2D6 into N-
desethylchloroquine (Projean, et al., 2003), which retains half of CQ’s antimalarial 
properties (McChesney & Fitch, 1984). CQ until recently was a widely used 
antimalarial due to its efficacy and low risk of side effects in prescribed doses. It was 
often combined with PR tablets. Since CQ also has a significant anti-pyretic and anti-
inflammatory effect when used to treat P. vivax infections, it may still remain useful 
even when resistance is more widespread. A slightly different drug called nivaquine 
or CQ phosphate has also been used.  
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However, due to improper use, parasite resistance developed rapidly, rendering the 
drug useless in many malaria endemic countries. Although the emergence of drug 
resistant parasitic strains is rapidly decreasing its effectiveness, it is still the first-line 
drug for malaria treatment in most sub-Saharan African countries. It is now 
suggested that it be used in combination with other antimalarial drugs to increase 
effectiveness. 
 
1.5.1(c) Piperaquine (PQ) 
Piperaquine (PQ), a bisquinoline, was used in China in the late 1970es and 1980es as 
malaria prophylaxis and treatment of CQ-resistant falciparum malaria due to its good 
tolerability and efficacy. It is structurally similar to CQ and highly lipophilic and 
hydrophobic (Sim, Davis, & Ilett, 2005); (Ahmed, et al., 2008). PQ exhibits elevated 
absorption and bioavailability in healthy volunteers when taken with moderately 
fatty meals (D'alessandro, 2009) maximising its therapeutic effects. 
Due to its rather extended elimination half-life (20 -33 days) (Hung, et al., 2004); 
(Tarning, et al., 2005); (Nguyen, et al., 2009), it is often co-administered with 
dihydroartemisinin (dHA) in ACTs. It is found to be effective against both 
falciparum and vivax malaria, with a mechanism that acts through chemical 
inhibition of parasite heme detoxification (Davis, Hung, Sim, Karunajeewa, & Ilett, 
2005). 
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1.5.1(d) Amodiaquine (AQ) 
Amodiaquine (AQ) has been used as falciparum malaria prophylaxis for over 40 
years (Foley & Tilley, 1998). It is a 4-aminoquinoline produced as an alternative to 
CQ. It is shown that AQ is highly effective in inhibiting growth of P.falciparum in 
vitro (Ekweozor, Aderounmu, & Sodeinde, 1987). It is intrinsically more active than 
CQ against P. falciparum parasites, which are moderately CQ resistant. The drug is 
therefore increasingly being considered as a replacement for chloroquine as a first 
line drug in Africa because of widespread CQ resistance.  
Because of major side effects, mainly agranulocytosis, observed during prophylactic 
use of the drug, AQ is now only recommended for treatment of malaria for which no 
serious cases of toxicity have been reported (Laurent, et al., 1993). After oral 
administration, AQ is rapidly absorbed and metabolized into mainly N-
desethylamodiaquine (DEAQ) with other minor metabolites, 2-hydroxyl-DEAQ and 
N-bisdesethylAQ (bis- DEAQ) (Churchill, Patchen, Campbell, Schwartz, Nguyen-
Dinh, & Dickinson, 1985); (Churchill, Mount, Patchen, & Björkman, 1986); (Mount, 
Patchen, Nguyen-Dinh, Barber, Schwartz, & Churchill, 1986). Although the 
formation of DEAQ is rapid, its elimination is very slow with a terminal half-life of 
over 100 h (Winstanley, Edwards, Orme, & Breckenridge, 1987); (Laurent, et al., 
1993). AQ and DEAQ both have antimalarial activity, but AQ is 3 times more active 
than its metabolite DEAQ (Churchill, Patchen, Campbell, Schwartz, Nguyen-Dinh, 
& Dickinson, 1985); (Li, Björkman, Andersson, Ridderström, & Masimirembwa, 
2002), produced through metabolism catalysed by hepatic enzyme CYP2C8 (Li, 
Björkman, Andersson, Ridderström, & Masimirembwa, 2002). However, since AQ is 
rapidly cleared and the metabolite DEAQ attains high plasma concentrations for a 
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long time, AQ is considered a prodrug. AQ is currently used in combination with 
artemisinin derivatives. 
 
1.5.1(e) Mefloquine (MQ) 
Quinolinemethanols, structural analogs of quinine (Hofheinz & Merkli, 1984) are 
potent drugs against both P.falciparum and P.vivax. Although some of the earlier 
compounds exhibited appreciable photosensitivity (Pullman, Eichelberger, Alving, 
Jones, Craige, & Whorton, 1948), a derivative with elevated efficacy and negligible 
photosensitivity was successfully developed. This derivative called mefloquine (MQ) 
is still utilized to treat malaria.  
MQ is an orally-administered antimalarial drug used as a prophylaxis against and for 
treatment of malaria. MQ is a very potent blood schizonticide and active against the 
erythrocytic stages of Plasmodium species. It is the drug of choice to treat malaria 
caused by chloroquine-resistant Plasmodium vivax (Maguire, Krisin, Marwoto, 
Richie, Fryauff, & Baird, 2006). MQ interferes with transportation of haemoglobin 
products and other substances from the host cell to the parasite’s food vacuole. 
However, the drug has no effect against the exoerythrocytic (hepatic) stages of the 
parasite.  
MQ is metabolized by the hepatic CYP3A4 into carboxymefloquine and 
hydroxymefloquine. The rather long half-life of MQ of about 20-30 days (Schwartz, 
et al., 1982); (Desjardins, Pamplin, von Bredow, Barry, & Canfield, 1979) and sub-
therapeutic concentrations of the drug which can remain in the blood for months after 
treatment, may contribute to emergence of parasite resistance (Karbwang & White, 
1990); (Nosten & Price, 1995). Parasite resistance towards MQ is evident especially 
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in Thailand and other parts of Southeast Asia. Therefore, MQ is now used in 
combination with artemisinin derivatives such as artesunate (AS) or artemether in 
order to stem further development of resistance (Price, et al., 1995). The sustained 
use of the AS-MQ combination has, in fact, reduced falciparum malaria transmission 
and progression of drug resistance in western Thailand (Nosten, et al., 2000); 
(Woodrow, Haynes, & Krishna, 2005). 
 
1.5.2. Antifolates 
Antifolates act by inhibiting the enzyme dihydrofolate reductase (DHFR) in the 
Plasmodium parasite (Yuthavong, 2002). DHFR is important in folate synthesis that 
forms the essential folate cofactor, fully-reduced tetrahydrofolate (Gregson & Plowe, 
2005). Tetrahydrofolate is vital for the production of purine and pyrimidine bases, 
which are necessary monomers in DNA synthesis. Low levels of tetrahydrofolate are 
known to arrest DNA replication in Plasmodium (Triglia & Cowman, 1999). 
Sulphonamides (SA), sulfones, pyrimethamine (PRY) and proguanil (PG) are among 
the most widely used antifolates (Figure 1.10). However, rapid emergences of 
resistance among Plasmodium towards these drugs are reducing its effectiveness 
(Olliaro & Yuthavong, 1999). 
PYR is used in the treatment of uncomplicated malaria. It is used in cases of CQ-
resistant P. falciparum strains when combined with sulphadoxine (a type of SA). It 
acts primarily on the schizonts during the hepatic and erythrocytic phases. 
Sulphadoxine acts on the schizonts during the hepatic and erythrocytic phases. It is 
mainly used for treating P. falciparum infections and is less active against other 
Plasmodium strains. However usage is restricted due to the long half life of the 
